Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
LLY 
Eli Lilly and Company (LLY)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
10/31/2025: LLY (3-star) is a STRONG-BUY. BUY since 32 days. Simulated Profits (13.10%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
29 Analysts rated it
Well-followed company, solid analyst reports, reliable data for confident investing.
1 Year Target Price $919.33
1 Year Target Price $919.33
| 16 | Strong Buy |
| 7 | Buy |
| 4 | Hold |
| 1 | Sell |
| 1 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 66.03% | Avg. Invested days 56 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 10/31/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 772.28B USD | Price to earnings Ratio 42.19 | 1Y Target Price 919.33 |
Price to earnings Ratio 42.19 | 1Y Target Price 919.33 | ||
Volume (30-day avg) 29 | Beta 0.46 | 52 Weeks Range 622.41 - 931.67 | Updated Date 10/31/2025 |
52 Weeks Range 622.41 - 931.67 | Updated Date 10/31/2025 | ||
Dividends yield (FY) 0.69% | Basic EPS (TTM) 20.45 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-10-30 | When Before Market | Estimate 6.37 | Actual 7.02 |
Profitability
Profit Margin 30.99% | Operating Margin (TTM) 47.65% |
Management Effectiveness
Return on Assets (TTM) 16.55% | Return on Equity (TTM) 86.29% |
Valuation
Trailing PE 42.19 | Forward PE 27.17 | Enterprise Value 771317873866 | Price to Sales(TTM) 13 |
Enterprise Value 771317873866 | Price to Sales(TTM) 13 | ||
Enterprise Value to Revenue 14.48 | Enterprise Value to EBITDA 39.23 | Shares Outstanding 895018757 | Shares Floating 895428470 |
Shares Outstanding 895018757 | Shares Floating 895428470 | ||
Percent Insiders 0.16 | Percent Institutions 83.65 |
Upturn AI SWOT
Eli Lilly and Company
Company Overview
History and Background
Eli Lilly and Company was founded in 1876 by Colonel Eli Lilly, a pharmaceutical chemist. Initially focused on manufacturing medications, it has evolved into a global pharmaceutical leader with significant milestones including the mass production of penicillin and the development of insulin.
Core Business Areas
- Human Pharmaceutical Products: Discovering, developing, manufacturing, and marketing pharmaceutical products for various disease areas, including diabetes, oncology, immunology, neuroscience, and cardiovascular diseases.
- Animal Health: Developing and marketing products for livestock and companion animals through its Elanco Animal Health division (now a separate publicly traded company after being spun off in 2019).
Leadership and Structure
The current CEO is David A. Ricks. The company operates with a functional organizational structure, with divisions focused on research & development, manufacturing, commercial operations, and corporate functions.
Top Products and Market Share
Key Offerings
- Market Share: High potential, market share is rapidly increasing in the GLP-1 receptor agonist market. Market share data is dynamic, influenced by competitor performance, insurance coverage, and supply constraints.
- Mounjaro (tirzepatide): A once-weekly injectable medication for the treatment of type 2 diabetes. Competitors include Novo Nordisk's Ozempic and Wegovy. Q4 2023 Revenue = $2.2 Billion
- Market Share: Significant market share in the GLP-1 receptor agonist market, but facing increasing competition from newer medications such as Mounjaro and Ozempic.
- Trulicity (dulaglutide): A once-weekly injectable medication for the treatment of type 2 diabetes. Competitors include Novo Nordisk's Ozempic. Q4 2023 Revenue = $1.6 Billion
- Market Share: Competitive market share in the CDK4/6 inhibitor market for breast cancer treatment.
- Verzenio (abemaciclib): A CDK4/6 inhibitor for the treatment of certain types of breast cancer. Competitors include Pfizer's Ibrance and Novartis' Kisqali. Q4 2023 Revenue = $1.1 Billion
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by intense competition, high R&D costs, stringent regulatory requirements, and a focus on innovation. Growth is driven by aging populations, increasing prevalence of chronic diseases, and advancements in biotechnology.
Positioning
Eli Lilly and Company is a major player in the pharmaceutical industry, with a strong presence in diabetes, oncology, and immunology. Its competitive advantages include a robust pipeline of innovative drugs, a strong global commercial infrastructure, and a commitment to R&D.
Total Addressable Market (TAM)
The global pharmaceutical market is estimated to reach over $1.7 trillion by 2027. Eli Lilly is well positioned to capture a significant share of this market through its innovative product portfolio and strong market presence.
Upturn SWOT Analysis
Strengths
- Strong R&D pipeline
- Established global presence
- Diverse product portfolio
- Expertise in diabetes and oncology
- Financial stability
Weaknesses
- Reliance on key products
- Exposure to patent expirations
- High R&D costs
- Regulatory scrutiny
- Competition from generic drugs
Opportunities
- Expanding into emerging markets
- Developing new therapies for unmet medical needs
- Leveraging digital health technologies
- Acquiring complementary businesses
- Collaborating with other companies
Threats
- Increasing competition
- Pricing pressures
- Regulatory changes
- Patent challenges
- Economic downturns
Competitors and Market Share
Key Competitors
- NVO
- MRK
- PFE
- ABBV
- JNJ
Competitive Landscape
Eli Lilly competes with other major pharmaceutical companies on the basis of product innovation, market access, and pricing. Its strong R&D pipeline and expertise in key therapeutic areas give it a competitive advantage.
Major Acquisitions
POINT Biopharma
- Year: 2023
- Acquisition Price (USD millions): 1400
- Strategic Rationale: Expanding oncology pipeline with radioligand therapies, which are promising cancer treatments.
Growth Trajectory and Initiatives
Historical Growth: Eli Lilly has experienced strong growth in recent years, driven by the success of its key products and strategic acquisitions.
Future Projections: Analysts expect Eli Lilly to continue to grow at a healthy pace, driven by its strong R&D pipeline and expanding market presence. Mounjaro and other pipeline products are expected to fuel growth.
Recent Initiatives: Recent strategic initiatives include the launch of new products, the acquisition of POINT Biopharma, and investments in R&D and manufacturing capacity.
Summary
Eli Lilly is a robust pharmaceutical company with a promising future, driven by innovative products like Mounjaro. The company's financial performance is strong, backed by a healthy R&D pipeline and strategic acquisitions. However, it must navigate increasing competition, pricing pressures, and patent expirations. Their oncology drug Verzenio is also doing well in its own market segment. Continued investment in R&D is important.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Eli Lilly and Company Investor Relations
- SEC Filings
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be construed as investment advice. Market share data is based on estimates and may vary. Past performance is not indicative of future results.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Eli Lilly and Company
Exchange NYSE | Headquaters Indianapolis, IN, United States | ||
IPO Launch date 1978-01-13 | Chairman, CEO & President Mr. David A. Ricks | ||
Sector Healthcare | Industry Drug Manufacturers - General | Full time employees 47000 | Website https://www.lilly.com |
Full time employees 47000 | Website https://www.lilly.com | ||
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; Verge Genomics; collaboration with AdvanCell to advance novel targeted alpha therapies for the treatment of cancer; and Chugai Pharmaceutical Co., Ltd; Strategic Collaboration with Eli Lilly to advance development of its myeloid engager platform for autoimmune disease, as well as Strategic partnership with NVIDIA Corporation for development of supercomputer. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.